BIOCORP Signs Two New Partnerships With Mallya Technology
17.2.2021 10:00:00 EET | Business Wire | Press release
Regulatory News:
BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME) (Paris:ALCOR), a French company specialized in the design, development and manufacturing of innovative medical devices, today announces the signature of new partnerships with Health2Sync and SocialDiabetes, companies headquartered in Taiwan and Spain, respectively.
These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
In detail, the platform developed by SocialDiabetes (CE marked and FDA 510K) allows self-monitoring of insulin doses and offers personalized recommendations to patients. All of the data collected feeds a telemedicine platform using augmented intelligence for physicians and specialized call centers. To date, this platform is used by 250,000 patients with diabetes, mainly in Spain, Mexico, Colombia and Chile.
Health2Sync’s app, through its analytics engine, provides personalized recommendations and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling way that encourages users to stay adherent to treatment plans. Health2Sync’s Patient Management Platform utilizes decision support modules for healthcare providers to deliver effective interventions that are also scalable, with insulin dosing as an example. The patient management platform is deployed in over 260 of diabetes care institutions in Taiwan, Malaysia and Japan, and the mobile app is used by more than 600,000 patients in Taiwan, Japan, USA, Hong Kong, Malaysia, Singapore and Australia.
Patients using these digital solutions will be able to automatically synchronize the data recorded by their Mallya sensor, thus benefiting from a complete monitoring offer combining glycemic data analysis and insulin dose feedback. This information can be transmitted in real time to treating physicians via a devoted portal to improve the quality of dialogue with patients, optimize treatment plans and offer personalized recommendations.
Éric Dessertenne, CEO of BIOCORP, explained: “These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market. Its integration with the most widely used applications in local markets is a great advantage for the rapid adoption of Mallya in these countries. Health2Sync and SocialDiabetes will enable us to accelerate our penetration in Asia and some Latin American countries, geographical areas where the diabetic population and the use of connected medicine are highly developed".
”Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Insulin dosing data captured by Mallya will significantly enhance the experience of patients on insulin “said Ed Deng, Co-Founder and CEO of Health2Sync. “We expect better adherence and improved outcomes that come as a result of making data available to patients and healthcare providers.”
“We are thrilled to initiate this agreement with Biocorp. Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers. Patients increasingly demand combined solutions that provide them with high connectivity and data driven personalized support. This alliance with Biocorp is a big step toward the digital health ecosystem the market is waiting for. “said María Jesús Salido, cofounder & CEO of Social Diabetes.
ABOUT HEALTH2SYNC
Founded in 2013, Health2Sync provides a comprehensive health-management platform for people with chronic conditions. Its products combine mobile, cloud, and data analytics, enabling patients to obtain personalized care and allows care providers and family to care for patients remotely. With the largest network of clinics and hospitals, it is the leading solution in Asia that brings an effective, yet scalable solution to diabetes management.
For more information, please visit https://www.health2sync.com
ABOUT SOCIAL DIABETES
SocialDiabetes is set to become one of the best solutions to foster the digital management of diabetes. Leader in Spanish speaking markets, the company, headquartered in Barcelona with offices in the UK, and Ciudad de Mexico was first created to meet the needs of Victor Bautista, a Type 1 diabetes patient and current CTO & co-founder. A company of patients working for patients, SocialDiabetes provides a system that synchronizes with multiple devices, easily connect patients with the healthcare professionals that are treating them and provides relevant information for decision making in one place.
For more information, please visit www.socialdiabetes.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005923/en/
Contact information
BIOCORP
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION
Bruno Arabian
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Nicolas Daniels
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom